Fig. 5.1
Protein synthesis system: Protein production is regulated and orchestrated by two signaling pathways: mTORC1 and UPR. Both pathways require ATP as an energetic currency, in which mTORC1 activation is the most energy-consuming pathway
5.2 Factors of Protein Synthesis Mechanisms in Podocytes
5.2.1 Adenosine Triphosphate (ATP) as Energy Currency in Podocytes
All living cells use ATP as a biological energy currency to perform the large number of intra- and extracellular events involved in metabolism, cell cycle, membrane transport, mechanical movement, and secretion. The main fuel of ATP production is glucose, which is processed by glycolysis in the cytoplasm and by the Krebs cycle and oxidative phosphorylation in the mitochondria. The respiratory chain complexes utilize NADH to generate a proton gradient in the inner mitochondrial membrane, enabling the production of large amounts of ATP by mitochondrial ATP synthase [3]. A measurement of oxygen consumption rates and extracellular acidification rates in a transformed mouse podocyte cell line using the Seahorse Bioscience XF24 Extracellular Flux Analyzer indicated that mitochondria play the primary role in maintaining podocyte energy homeostasis, while glycolysis provides a lesser contribution [4]. Accumulated evidence has revealed the clear cross talk between podocyte mitochondrial dysfunction and glomerular proteinuria. For instance, an A to G transition at position 3243 in mitochondrial DNA (A3243G) is associated with myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) and progressive external ophthalmoplegia (PEO) [5]. However, many patients with the A3243G mutation initially present with nephrotic syndrome, without any sign of MELAS and PEO [6–8]. The pathogenesis of glomerular proteinuria in such patients could be explained by podocyte injury. Their glomerular pathology indicates focal segmental glomerulosclerosis, a typical podocyte disease. These reports suggest that the podocyte energy system plays an indispensable role in the integrity of the glomerular permselective barrier.
5.2.2 Glucose
Although glucose is a major fuel for intracellular ATP as described above, it is unclear whether hypoglycemia itself leads to podocyte dysfunction and causes glomerular proteinuria. To explore this question, it is essential to develop an animal model exhibiting long-term hypoglycemia. On the other hand, more than three decades ago, one preliminary clinical trial studied in juvenile diabetics. In that study, the patients were treated with intravenous insulin in combination with glucose infusion to maintain blood glucose levels. The results were intriguing in that urinary albumin excretion approximately doubled after insulin infusion, from 6.8 to 12.5 microgram/min, without a significant change in the glomerular filtration rate or renal plasma flow [9]. Recently, mice with a specific deletion of the insulin receptor from podocytes developed significant albuminuria together with histological features that recapitulated diabetic nephropathy, but in a normoglycemic environment [10]. The authors further demonstrated that an insulin signaling cascade in podocytes through the mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K) pathways via the insulin receptor directly remodels the actin cytoskeleton [10]. Although the data between these two studies may appear contradictory, it is clear that pathways downstream of insulin signaling exist in podocytes. These may underlie the physiology and pathology of glomerular proteinuria.
Since the 1990s, molecular and functional cloning methods have identified many transporter families for each nutrient (refer to SLC TABLE: http://www.bioparadigms.org/slc/intro.htm). Glucose is taken into cells through the glucose transporters (GLUTs) at the plasma membrane, of which there are currently 14 known members [11]. Although studies revealed GLUT1, GLUT3, GLUT4, and GLUT8 to be expressed in the glomerulus, whether these isoforms indeed exist and function in podocytes and how they are involved in energy production under physiological and pathological conditions require additional studies [12]. GLUT4 is the most studied isoform in podocyte biology. Glucose uptake by insulin in podocytes is conducted through the translocation of GLUT4 and GLUT1, depending on the filamentous actin cytoskeleton [13]. Podocyte-specific GLUT4-deficient mice do not develop proteinuria, despite having larger and fewer podocytes than wild type, and are also protected from diabetes-induced hypertrophy due to the failure to activate mTOR [14]. In contrast, GLUT4-deficient mice treated with the mTOR inhibitor (mTORI) rapamycin developed worse adriamycin-induced nephropathy than WT mice [14]. This contradiction regarding the altered podocyte sensitivity to different insults in GLUT4-deficient mice indicates the complicated interaction between glucose and the signaling pathway.
5.2.3 Amino Acids
Amino acid intake across the plasma membrane is mediated by amino acid transporters. The L amino acid transporter (LAT) family prefers branched-chain amino acids (BCAA) as their substrates [15, 16]. Four LATs (LAT1–LAT4) have been identified, and LAT3 is the only amino acid transporter that locates at the plasma membrane and responds to amino acids in podocytes. LAT3 was first identified by expression cloning in a human hepatocarcinoma cell line [17]. We thereafter proved that LAT3 is sensitive to nutritional depletion in the liver and skeletal muscle [18]. In addition, it was clearly revealed that LAT3 is one of the major routes to provide podocytes with BCAAs. The effect of nutrition on podocyte LAT3 is intriguing. Food starvation upregulates LAT3 and phosphorylated oncogene identified in the AKT8 retrovirus (AKT) 1 (AKT1, S473) in podocytes, accompanied by the reconstitution of the actin network and foot process elongation [19]. However, the direct relevance of LAT3 function in podocyte energy metabolism remains to be further elucidated. Despite LAT1’s known expression in malignant cells [20–22], its plasma membrane expression in normal tissues has only been reported in the vascular endothelial cells forming the blood–brain barrier [23, 24] and syncytiotrophoblastic cells of the placenta [25]. LAT2 is expressed in the plasma membrane of the normal epithelium of the kidney proximal tubules and the digestive tract [26–30], while LAT4 locates to the renal distal tubules and collecting ducts [31]. Importantly, both LAT1 and LAT2 require binding to 4 F2 cell-surface antigen heavy chain (4F2hc) to form a heterodimeric complex via disulfide bonds, which is essential for their localization in the plasma membrane [30, 32]. We revealed that both LAT1 and LAT2 exist in the cytoplasm but not in the plasma membrane in normal podocytes [33]. The absence of plasma membrane localization of both isoforms is possibly explained by the lack of 4F2hc protein in normal podocytes. Interestingly, in the model of crescentic glomerulonephritis, both LAT2 and 4F2hc mRNA are upregulated in podocytes as well as in Bowman’s cells, and their proteins are relocated to the plasma membrane. This action occurs prior to the crescent formation [33]. This phenomenon suggests that LAT2 plays a biological role underlying cell proliferation in glomerulonephritis, but it is still unclear whether this isoform also underlies the pathogenesis of proteinuria in nephrotic syndrome.
5.2.4 Nucleosides
Nucleosides are salvaged back to nucleoside triphosphates including ATP, guanosine triphosphate (GTP), cytidine triphosphate (CTP), 5-methyluridine triphosphate (m5UTP), and uridine triphosphate (UTP) in the cell cytosol, with the exception of inosine, whose salvage is limited to inosine monophosphate. Nucleoside triphosphates supply energy and phosphate groups for phosphorylation and therefore play a fundamental role in the physiology of many organs. Nucleosides also require their own transporters for their import into the cell cytosol. Mammalian cells possess two major nucleoside transporter families: the equilibrative nucleoside transporters (ENTs) mediate nucleoside transport in both directions depending on the nucleoside concentration gradient across the plasma membrane, and the concentrative nucleoside transporters (CNTs) mediate nucleoside transport independent of the nucleoside concentration gradient across the plasma membrane [34–37]. Although the mRNA expression pattern of the nucleoside transporters varies among organs and species [38], protein expression in organs including the kidney remains largely unsolved. It is reported that the mRNAs of CNT isoforms 1–3 are expressed through the rat nephron, and CNT 2 is the predominant isoform in the glomerulus [39]. We further identified the protein of this isoform expressed in the podocytes of the human kidney glomerulus [40]. Adenosine is the main nucleoside relevant to energy metabolism, which is taken up by mammalian cells through ENT1 and CNT2. Adenosine activates adenosine monophosphate-activated kinase (AMPK), a central sensor of the intracellular energy status [41–43]. Thus, CNT2 in podocytes seems to play a fundamental role in glomerular physiology and pathology by regulating the intracellular adenosine content through controlling AMPK activation.
Both quiescent and damaged cells release ATP outside the cell. Those cells recognize extracellular ATP through P2X ATP receptors, which in turn induce autocrine purinergic signaling activation [44]. Ectonucleotidases rapidly hydrolyze ATP to ADP, AMP, and adenosine on the cell surface [45], which in turn activate many signaling pathways through binding to P2Y nucleotide receptors and P1 adenosine receptors [44]. The reuptake of adenosine via nucleoside transporters (ENT1 and CNT2) is important for ATP generation inside cells [41]. Podocytes express P1 adenosine receptors (A1 and A2a) in the rat kidney [46, 47]. However, how these receptors are involved in the pathogenesis of glomerular proteinuria in nephrotic syndrome remains unknown.
5.3 Regulatory Mechanism of Protein Synthesis
5.3.1 Energy-Consuming Process: Mechanistic/Mammalian Target of Rapamycin (mTOR)
The maintenance of protein expression in a cell is tightly regulated by an equilibrium between synthesis and degradation. Protein synthesis occurs via the specific signaling pathway activated through mTOR (mechanistic target of rapamycin, formerly known as the mammalian target of rapamycin). mTOR is an evolutionarily conserved serine/threonine kinase that was first identified from dominant missense mutations in yeast resistant to the immunosuppressant rapamycin [48, 49]. mTOR forms two functional complexes, mTOR complex1 (mTORC1) and mTOR complex2 (mTORC2) [50]. mTORC1 contains mTOR, raptor, mLST8, and PRAS40, whereas mTORC2 is composed of mTOR, rictor, mLST8, mSin1, and protor [51–54]. The activation of the mTORC1 pathway stimulates both the initiation and elongation phases of mRNA translation and increases ribosome biogenesis, thereby accelerating cell size enlargement and cell proliferation [55]. mTORC1 activation occurs through sensing upstream stimuli, including nutrients (e.g., amino acids), growth factors (insulin), and the cellular energy status (ATP/AMP ratio) [56]. This activation then phosphorylates many downstream targets, including 4E-BP1, S6K, and LARP1 [57]. Recent studies indicate that mTOR also modulates mitochondrial functions, stimulating the synthesis of nucleus-encoded mitochondria-related proteins such as mitochondrial ribosomal proteins, components of complexes I and V, and TFAM [58]. These signaling pathways that drive protein production require massive amounts of energy and are therefore called energy-consuming pathways. Compared to mTORC1, which is sensitive to acute rapamycin treatment, mTORC2 is only sensitive to prolonged treatment [59]. Currently, mTORC2 is known to phosphorylate Akt/protein kinase B, protein kinase C, and serum- and glucocorticoid (GC)-induced kinase, thereby being involved in actin reorganization and regulating metabolism, cell survival, and Na+ transport [60]. However, how much intracellular energy the mTORC2 pathway consumes is still unclear.
5.3.2 Energy-Economizing Process: Unfolded Protein Response (UPR) and Endoplasmic Reticulum Stress (ER Stress)
Many cellular events are orchestrated by antagonistic pathways or molecules to maintain cell survival and viability such as oxidation vs. antioxidation and apoptosis vs. survival. Together with active energy-consuming systems such as the mTORC1 pathway mentioned above, cells are equipped with so-called anti-energy-consuming pathways or energy-economizing pathways that halt protein production. During protein production, glycoproteins undergo special and precise processes to be transported to their final destination. Only accurately folded proteins are allowed to exit the endoplasmic reticulum (ER) and be transported to the Golgi compartment. Unfolded and misfolded proteins are either retained in the ER in a complex with molecular chaperones or degraded in a process referred to as ER-associated degradation [61]. When these immature proteins accumulate beyond the ER handling capacity, so-called ER stress occurs and promotes cell survival by arresting protein translation and stimulating the gene expression of molecular chaperones [62]. This signaling pathway linking ER imbalance to gene expression is named the unfolded protein response (UPR). The concept of UPR was initiated by the identification of two membrane proteins that were induced in avian sarcoma virus-transformed cells [63]. Induction of glucose-regulated proteins 78 and 98, referred to as GRP78 and GRP94, was not a direct effect of cellular transformation, but was secondary to the rapid depletion of glucose from the growth medium of rapidly growing sarcoma virus-transformed fibroblasts [64]. Further studies identified GRP78 (alternatively named BiP) as a representative ER-resident chaperone that is bound to polypeptides and regulates protein folding in the ER [65, 66]. In addition, other ER chaperones, including calreticulin, play crucial roles in the trimming of sugar bonds from glycoproteins and in correct folding. It is important to note that these ER chaperones successfully function in the presence of sufficient ATP. Therefore, the lack of ATP leads to the upregulation of ER chaperones, in which GRP78/BiP up-expression is a commonly used indicator to determine that cells undergo UPR/ER stress.
5.4 UPR/ER Stress and Glomerular Proteinuria
The involvement of UPR/ER stress in the pathogenesis of glomerular disease is a relatively new story [12, 67, 68]. The first report indicating the role of ER stress in glomerular proteinuria was demonstrated in Heymann nephritis, a rat model of human membranous nephropathy [69, 70]. This study revealed that GRP78 was upregulated and that both PERK and eIF2α, downstream UPR molecules, were activated in the glomeruli at the proteinuric stage. Subsequently, another group demonstrated a pathogenic role for the accumulation of misfolded proteins in the ER in glomerular podocytes in vivo. A transgenic rat overexpressing megsin, a member of the serine protease inhibitor family, developed massive proteinuria [71, 72]. Recently, Pierson syndrome, a congenital nephrotic syndrome with a mutation in the laminin β2 gene, was suggested as a prototypical ER storage disease. Authors generated transgenic mice carrying a mild laminin β2 missense mutation. This mutation caused defective secretion of laminin α5β2γ1 from the podocyte to the glomerular basement membrane (GBM). Interestingly, in this animal model ER stress preceded proteinuria and was still associated with proteinuric stage [73]. These in vivo models support the idea that excess protein accumulation in podocytes causes glomerular proteinuria through activating UPR/ER stress. Therefore, does ER stress also underlie the pathogenesis of proteinuria in acquired nephrotic syndrome? Puromycin aminonucleoside (PAN) nephrosis is a well-known rat model resembling minimal change nephrotic syndrome (MCNS) [74]. However, the pathogenesis of proteinuria has remained unclear. Previously, we revealed that glomeruli at the proteinuric stage of PAN nephrosis exhibited an upregulation of GRP78 mainly in the podocyte [40]. In vitro experiments further determined that energy depletion resulted in the accumulation of hypoglycosylated immature nephrin in the ER associated with UPR activation (GRP78 upregulation). Interestingly, the hypoglycosylation and mislocalization of nephrin were rescued by treatment with GC and mizoribine through the recovery of intracellular ATP [40, 75, 76]. These experiments led us to hypothesize that the arrested protein production of nephrin under ER stress was a main cause of proteinuria in PAN nephrosis.
5.5 mTORC1 Activation Upstream of UPR/ER Stress in Glomerular Proteinuria
As described so far, in the protein production system, mTORC1 accelerates production associated with energy consumption, whereas UPR halts the process to economize energy. Therefore, these two signaling networks have been understood as separate pathways that are involved in different cellular processes. However, recent studies, including ours, indicate that tight interconnections between mTORC1 and UPR activation also underlie many pathological events [77–80]. The first evidence showing the cross talk between UPR/ER stress and the chronic activation of mTORC1 emerged in 2008. It was revealed that loss of function of the tuberous sclerosis complex genes (TSC1 or TSC2) led to constitutive activation of the mTORC1 signaling pathway, resulting in the development of tumors and neurological disorders [77]. Interestingly, this loss of TSC1 or TSC2 also caused ER stress and activated UPR [77]. This was further demonstrated in a murine model of diabetic nephropathy (DN). DN is speculated to be a podocyte disease. However, the molecular mechanisms of podocyte dysfunction in the development of DN remain unclear. A study revealed that mTORC1 activity was enhanced in the podocytes of diabetic animals [81]. Podocyte-specific mTORC1 activation induced by ablation of an upstream negative regulator (PcKOTsc1) resulted in podocyte loss, GBM thickening, mesangial expansion, and proteinuria in nondiabetic young and adult mice [81]. In this model, abnormal mTORC1 activation induced the mislocalization of nephrin with enhanced ER stress in podocytes. 4-Phenyl butyric acid, a chemical chaperone that reduced UPR/ER stress, is protected against both the podocyte phenotypic switch and podocyte loss in PcKOTsc1 mice [81]. These previous studies indicate that mTORC1 activation is a critical step that leads to UPR/ER stress in podocytes, which may be a directly responsible event underlying the pathology of glomerular proteinuria.
Could be the same scenario as described in DN be adopted for the pathology of MCNS? One interesting paper showed that pretreatment with mTORI (everolimus) significantly protected against proteinuria in PAN nephrosis [82]. The authors, however, proposed that the protective effect of mTORI was due to a reduction in macrophage invasion and not a direct effect against podocyte injury. To identify the interconnection between mTORC1 activation and UPR/ER stress induction in this model, we consecutively analyzed the glomeruli between day 0 and day 5 after PAN injection [79]. Significant proteinuria was initiated on day 2 after PAN injection. In the control glomeruli from mice treated with saline, the majority of the GRP78 staining was observed in the cytoplasm of the podocyte cell bodies. In contrast, in day 1 glomeruli after PAN injection, which is 1 day prior to proteinuria, increased GRP78 was found in the podocytes, including the foot processes. On and after day 2, the GRP78 podocyte expression increased in association with the exacerbation of proteinuria. In the control glomeruli, nephrin was demonstrated as having a GBM pattern, indicating its proper localization at the slit membrane. In contrast, the overall distribution of nephrin in days 1 and 2 glomeruli consisted of a GBM pattern and a podocyte cytoplasmic pattern, and clear overlap of cytoplasmic nephrin with GRP78 was determined. These results indicated that some nephrin was retained in the podocyte cytoplasm. On days 3 and 5, GBM-pattern nephrin was drastically reduced and the majority of nephrin was cytoplasmic and colocalized with GRP78. In addition, in day 1 and day 2 glomeruli, low molecular weight, or immature, nephrin was observed, and nephrin mRNA was rather increased. These results suggested that UPR–ER stress occurred in podocytes and immature nephrin accumulated in the ER, leading to structural defects in the slit membrane and causing heavy glomerular proteinuria. With the studies using the sample from in vivo such as isolated glomeruli, it is difficult to conclusively distinguish the time lag between the rapid activation of the signaling pathways. In cultured podocyte experiments treated with PAN, mTORC1 activation actually preceded UPR activation [79]. In an in vivo model, PAN rats treated with mTORI (everolimus) clearly showed inhibition of proteinuria and also preserved nephrin expression. All the cellular signaling pathways demand energy that is driven by the hydrolysis of ATP to ADP and phosphate or AMP and pyrophosphate. The energy charge, which is defined as {[ATP] + §[ADP]}/{[ATP] + [ADP] + [AMP]}, reflects the cellular balance between the energy-consuming state and the energy-producing state [83]. The energy charge implies that AMP drives the cellular energy balance toward the energy-producing adaptation [84]. In our nephrotic syndrome model, AMPKα, a sensor of glomerular energy status, was activated after mTORC1 activation. In addition, the intracellular ATP levels in cultured podocytes decreased after mTORC1 activation, with a concurrent increase in the AMP levels, whereas the ADP levels showed no significant change. Overall, these changes represent a marked decrease in the energy charge [79], and this finding indicates that the cells appeared to be shifted to an energy-deficient state. Indeed, when PAN rats were treated with everolimus after PAN injection, proteinuria was not changed at all (unsubmitted data), conclusively indicating that mTORC1 activation is a primary cause of PAN nephrosis. Lipopolysaccharide (LPS) is also a well-known inducer of nephrotic syndrome in mice [85]. LPS activates a signaling pathway through interaction with toll-like receptor 4 [86, 87]. However, its mechanism of inducing proteinuria remains elusive. Interestingly, LPS activated mTORC1 in the glomerular podocytes during the proteinuric state [12]. We did not continuously evaluate the LPS-treated mice because the proteinuric phase of this model is very short, starting at 12 h and disappearing at 48 h after LPS injection [88]. Instead, cultured podocytes were treated with LPS and consecutively analyzed for changes in signaling activity. LPS treatment for 3 h activated phospho-70S6K, a downstream target of mTORC1, and AMPKα. These proteins remained active for 48 h [12].
In conclusion, mTORC1 activation seems to act upstream and secondarily induce UPR/ER stress in podocytes, thereby affecting the integrity of the podocyte filtration barrier and leading to heavy glomerular proteinuria.
5.6 mTOR Inhibitor Causes Glomerular Proteinuria
A great deal of mystery confounds the idea that mTORC1 activation triggers UPR/ER stress and leads to glomerular proteinuria. mTORI was originally used to replace calcineurin inhibitor to avoid nephrotoxicity and maintain kidney function in organ transplant patients [89, 90]. Subsequently, based on its antiproliferative and antiangiogenic effects, mTORI has also been used in the treatment of cancers such as renal cell carcinoma [91] and nonmalignant conditions such as autosomal dominant polycystic kidney disease [92]. However, mTORI causes a variety of adverse effects in many organs, including blood cells. Glomerular proteinuria is one of its well-known effects [93]. Exacerbated proteinuria occurs in up to approximately 40 % of kidney transplant patients, but the incidence of nephrotic syndrome is low (2 % for sirolimus) [93]. A randomized clinical study of autosomal dominant polycystic kidney disease revealed a significantly increased urinary albumin excretion rate in the sirolimus group compared to the control group, suggesting that the induction of sirolimus itself may cause de novo proteinuria. The mechanism by which mTORI causes proteinuria remains elusive. It has been reported that the combination of low-dose everolimus and low-dose CNI does not cause proteinuria in pediatric renal transplant patients [94, 95]. On the other hand, conversion of CNI to sirolimus revealed an apparent increase of proteinuria [96]. Thus, one hypothesis speculates that the elimination of the vasoconstrictive effects of CNI may underlie the pathogenesis of proteinuria. Reduction of vascular endothelial growth factor (VEGF) expression is also hypothesized as another cause of proteinuria. mTORI (rapamycin) exerts antiangiogenic effects linked to decreased VEGF production and also inhibits the response of vascular endothelial cells to VEGF stimulation [97, 98]. VEGF is prominently expressed in glomerular podocytes and in tubular epithelial cells in the kidney, while VEGF receptors are mainly found on preglomerular, glomerular, and peritubular endothelial cells [99]. Interestingly, mice heterozygous for VEGF-A in the podocyte exhibited endotheliosis and loss of endothelial fenestration, leading to nephrotic syndrome [100]. Presently, no definite evidence can explain a direct involvement of downregulation of mTOR and inactivation of mTORC1 signaling in the induction of UPR/ER stress. However, this idea is worth studying in the future.
5.7 Energy Metabolism in the Podocyte as a Therapeutic Target
Energy metabolism pathways, especially in mitochondria, have emerged as new therapeutic targets in many intractable diseases, including kidney diseases [101–103]. Over the past five decades, synthetic GCs have been employed as a first-line treatment for patients with acquired nephrotic syndrome. Despite their obvious clinical effect on nephrotic syndrome, especially with the minimal change patients, how GCs improve heavy proteinuria is largely unknown. The pharmacological action of GCs is executed principally through binding to a cytosolic receptor, the glucocorticoid receptor (GR) [104, 105]. Although blood lymphocytes are the most likely GC therapeutic target, the injured glomerular podocytes are also considered to undergo GC effects. In 1999, we discovered that all human glomerular cells possess GR both in the cytoplasm and in the nucleus, where GR is dynamically translocated between both compartments [106]. We additionally revealed that the glucocorticoid-inactivating enzyme 11β-hydroxysteroid dehydrogenase type 2 functions in human glomerular podocytes [107]. Thus, we proposed that GCs may directly act on the injured glomerular podocytes and that GCs are metabolized in these highly differentiated cells. We also showed that the mitochondria in glomerular podocytes expressed the GR and that GC stimulated ATP production through the upregulation of mitochondrial genes [76]. The protective effect of GCs on ER-stressed cells was obvious in our in vitro nephrotic syndrome model. However, there is no doubt that GCs possess pharmacological functions with more effects on the energy regulatory machinery than those that we have proposed thus far. In conclusion, a better understanding of energy metabolism in activated and quiescent podocytes will provide insights into the elucidation of many pathologies and the development of future therapeutic interventions.
References
1.
Rolfe DF, Brown GC. Cellular energy utilization and molecular origin of standard metabolic rate in mammals. Physiol Rev. 1997;77:731–58.PubMed
2.
Buttgereit F, Brand MD. A hierarchy of ATP-consuming processes in mammalian cells. Biochem J. 1995;312:163–7.PubMedCentralPubMed
3.
von Ballmoos C, Wiedenmann A, Dimroth P. Essentials for ATP synthesis by F1F0 ATP synthases. Annu Rev Biochem. 2009;78:649–72. doi:10.1146/annurev.biochem.78.081307.104803.
4.
Abe Y, Sakairi T, Kajiyama H, Shrivastav S, Beeson C, Kopp JB. Bioenergetic characterization of mouse podocytes. Am J Physiol Cell Physiol. 2010;299:C464–76. doi:10.1152/ajpcell.00563.2009.PubMedCentralPubMed
5.
Shoffner JM. Maternal inheritance and the evaluation of oxidative phosphorylation diseases. Lancet. 1996;348:1283–8.PubMed
6.
Kurogouchi F, Oguchi T, Mawatari E, Yamaura S, Hora K, Takei M, et al. A case of mitochondrial cytopathy with a typical point mutation for MELAS, presenting with severe focal-segmental glomerulosclerosis as main clinical manifestation. Am J Nephrol. 1998;18:551–6.PubMed
7.
Jansen JJ, Maassen JA, van der Woude FJ, Lemmink HA, van den Ouweland JM, t’ Hart LM, et al. Mutation in mitochondrial tRNA(Leu(UUR) gene associated with progressive kidney disease. J Am Soc Nephrol. 1997;8:1118–24.PubMed
8.
Hotta O, Inoue CN, Miyabayashi S, Furuta T, Takeuchi A, Taguma Y. Clinical and pathologic features of focal segmental glomerulosclerosis with mitochondrial tRNALeu(UUR) gene mutation. Kidney Int. 2001;59:1236–43.PubMed
9.
Mogensen CE, Christensen NJ, Gundersen HJ. The acute effect of insulin on heart rate, blood pressure, plasma noradrenaline and urinary albumin excretion. The role of changes in blood glucose. Diabetologia. 1980;18(6):453–7.PubMed
10.
Welsh GI, Hale LJ, Eremina V, Jeansson M, Maezawa Y, Lennon R, et al. Insulin signaling to the glomerular podocyte is critical for normal kidney function. Cell Metab. 2010;12:329–40. doi:10.1016/j.cmet.2010.08.015.PubMed
11.
Thorens B, Mueckler M. Glucose transporters in the 21st Century. Am J Physiol Endocrinol Metab. 2010;298:E141–5. doi:10.1152/ajpendo.00712.2009.PubMedCentralPubMed
12.
Yan K, Ito N, Nakajo A, Kurayama R, Fukuhara D, Nishibori Y, Kudo A, Akimoto Y, Takenaka H. The struggle for energy in podocytes leads to nephrotic syndrome. Cell Cycle. 2012;11:1504–11. doi:10.4161/cc.19825.PubMed
13.
Coward RJ, Welsh GI, Yang J, Tasman C, Lennon R, Koziell A, et al. The human glomerular podocyte is a novel target for insulin action. Diabetes. 2005;54:3095–102.PubMed
14.
Guzman J, Jauregui AN, Merscher-Gomez S, Maiguel D, Muresan C, Mitrofanova A, et al. Podocyte-specific GLUT4-deficient mice have fewer and larger podocytes and are protected from diabetic nephropathy. Diabetes. 2014;63:701–14. doi:10.2337/db13-0752.PubMedCentralPubMed
15.
Christensen HN. Role of amino acid transport and countertransport in nutrition and metabolism. Physiol Rev. 1990;70:43–77.PubMed
16.
PalacÚn M, EstÕvez R, Bertran J, Zorzano A. Molecular biology of mammalian plasma membrane amino acid transporters. Physiol Rev. 1998;78:969–1054.
17.
Babu E, Kanai Y, Chairoungdua A, Kim DK, Iribe Y, Tangtrongsup S, et al. Identification of a novel system L amino acid transporter structurally distinct from heterodimeric amino acid transporters. J Biol Chem. 2003;278:43838–45.PubMed
18.
Fukuhara D, Kanai Y, Chairoungdua A, Babu E, Bessho F, Kawano T, et al. Protein characterization of Na+ -independent system L amino acid transporter 3 in mice. Am J Pathol. 2007;170:888–98.PubMedCentralPubMed
19.
Sekine Y, Nishibori Y, Akimoto Y, Kudo A, Ito N, Fukuhara D, et al. Amino acid transporter LAT3 is required for podocyte development and function. J Am Soc Nephrol. 2009;20:1586–96.PubMedCentralPubMed
20.
Rosilio C, Nebout M, Imbert V, Griessinger E, Neffati Z, Benadiba J, et al. L-type amino-acid transporter 1 (LAT1): a therapeutic target supporting growth and survival of T-cell lymphoblastic lymphoma/T-cell acute lymphoblastic leukemia. Leukemia. 2014. doi:10.1038/leu.2014.338.PubMed
21.
Yanagida O, Kanai Y, Chairoungdua A, Kim DK, Segawa H, Nii T, et al. Human L-type amino acid transporter 1 (LAT1): characterization of function and expression in tumor cell lines. Biochim Biophys Acta. 2001;1514:291–302.PubMed
22.
Nakanishi K, Matsuo H, Kanai Y, Endou H, Hiroi S, Tominaga S, et al. LAT1 expression in normal lung and in atypical adenomatous hyperplasia and adenocarcinoma of the lung. Virchows Arch. 2006;448:142–50.PubMed
23.
Matsuo H, Tsukada S, Nakata T, Chairoungdua A, Kim DK, Cha SH, et al. Expression of a system L neutral amino acid transporter at the blood-brain barrier. Neuroreport. 2000;11:3507–11.PubMed
24.
Kageyama T, Nakamura M, Matsuo A, Yamasaki Y, Takakura Y, Hashida M, et al. The 4F2hc/LAT1 complex transports L-DOPA across the blood-brain barrier. Brain Res. 2000;879:115–21.PubMed
25.
Ritchie JW, Taylor PM. Role of the system L permease LAT1 in amino acid and iodothyronine transport in placenta. Biochem J. 2001;356:719–25.PubMedCentralPubMed
26.
Park SY, Kim JK, Kim IJ, Choi BK, Jung KY, Lee S, et al. Reabsorption of neutral amino acids mediated by amino acid transporter LAT2 and TAT1 in the basolateral membrane of proximal tubule. Arch Pharm Res. 2005;28:421–32.PubMed
27.
Dave MH, Schulz N, Zecevic M, Wagner CA, Verrey F. Expression of heteromeric amino acid transporters along the murine intestine. J Physiol. 2004;558:597–610.PubMedCentralPubMed
28.
Pineda M, Fernández E, Torrents D, Estévez R, López C, Camps M, et al. Identification of a membrane protein, LAT-2, that co-expresses with 4F2 heavy chain, an L-type amino acid transport activity with broad specificity for small and large zwitterionic amino acids. J Biol Chem. 1999;274:19738–44.
29.
Segawa H, Fukasawa Y, Miyamoto K, Takeda E, Endou H, Kanai Y. Identification and functional characterization of a Na + −independent neutral amino acid transporter with broad substrate selectivity. J Biol Chem. 1999;274:19745–51.PubMed
30.
Rossier G, Meier C, Bauch C, et al. LAT2, a new basolateral 4F2hc/CD98-associated amino acid transporter of kidney and intestine. J Biol Chem. 1999;274:34948–54.PubMed
31.
Bodoy S, MartÚn L, Zorzano A, PalacÚn M, EstÕvez R, Bertran J. Identification of LAT4, a novel amino acid transporter with system L activity. J Biol Chem. 2005;280:12002–11.PubMed
32.
Kanai Y, Segawa H, Miyamoto K, Uchino H, Takeda E, Endou H. Expression cloning and characterization of a transporter for large neutral amino acids activated by the heavy chain of 4F2 antigen (CD98). J Biol Chem. 1998;273:23629–32.PubMed
33.
Kurayama R, Ito N, Nishibori Y, Fukuhara D, Akimoto Y, Higashihara E, et al. Role of amino acid transporter LAT2 in the activation of mTORC1 pathway and the pathogenesis of crescentic glomerulonephritis. Lab Invest. 2011;81:992–1006. doi:10.1038/labinvest.2011.43.
34.
Gray JH, Owen RP, Giacomini KM. The concentrative nucleoside transporter family, SLC28. Pflugers Arch. 2004;447:728–34.PubMed
35.
Baldwin SA, Beal PR, Yao SY, King AE, Cass CE, Young JD. The equilibrative nucleoside transporter family, SLC29. Pflugers Arch. 2004;447:735–43.PubMed
36.
Kong W, Engel K, Wang J. Mammalian nucleoside transporters. Curr Drug Metab. 2004;5:63–84.PubMed
37.
Molina-Arcas M, Casado FJ, Pastor-Anglada M. Nucleoside transporter proteins. Curr Vasc Pharmacol. 2009;7:426–34.PubMed
38.
Podgorska M, Kocbuch K, Pawelczyk T. Recent advances in studies on biochemical and structural properties of equilibrative and concentrative nucleoside transporters. Acta Biochim Pol. 2005;52:749–58.PubMed
39.
Rodriguez-Mulero S, Errasti-Murugarren E, Ballarin J, Felipe A, Doucet A, Casado FJ, et al. Expression of concentrative nucleoside transporters SLC28 (CNT1, CNT2, and CNT3) along the rat nephron: effect of diabetes. Kidney Int. 2005;68:665–72.PubMed
40.
Nakajo A, Khoshnoodi J, Takenaka H, Hagiwara E, Watanabe T, Kawakami H, et al. Mizoribine corrects defective nephrin biogenesis by restoring intracellular energy balance. J Am Soc Nephrol. 2007;18:2554–64.PubMed
41.
Aymerich I, Foufelle F, FerrÕ P, Casado FJ, Pastor-Anglada M. Extracellular adenosine activates AMP-dependent protein kinase (AMPK). J Cell Sci. 2006;119:1612–21.PubMed
42.
Inoki K, Kim J, Guan KL. AMPK and mTOR in cellular energy homeostasis and drug targets. Annu Rev Pharmacol Toxicol. 2012;52:381–400. doi:10.1146/annurev-pharmtox-010611-134537.PubMed
43.
Hardie DG. AMP-activated protein kinase: an energy sensor that regulates all aspects of cell function. Genes Dev. 2011;25:1895–908. doi:10.1101/gad.17420111.PubMedCentralPubMed
44.
Junger WG. Immune cell regulation by autocrine purinergic signalling. Nat Rev Immunol. 2011;11:201–12. doi:10.1038/nri2938.PubMedCentralPubMed
45.
Yegutkin GG. Nucleotide- and nucleoside-converting ectoenzymes: important modulators of purinergic signalling cascade. Biochim Biophys Acta. 2008;1783:673–94. doi:10.1016/j.bbamcr.2008.01.024.PubMed
46.
Vallon V, Mühlbauer B, Osswald H. Adenosine and kidney function. Physiol Rev. 2006;86:901–40.PubMed
47.
Pawelczyk T, Grden M, Rzepko R, Sakowicz M, Szutowicz A. Region-specific alterations of adenosine receptors expression level in kidney of diabetic rat. Am J Pathol. 2005;167:315–25.PubMedCentralPubMed
48.
Heitman J, Movva NR, Hall MN. Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science. 1991;253:905–9.PubMed
49.
Cafferkey R, Young PR, McLaughlin MM, Bergsma DJ, Koltin Y, Sathe GM, et al. Dominant missense mutations in a novel yeast protein related to mammalian phosphatidylinositol 3-kinase and VPS34 abrogate rapamycin cytotoxicity. Mol Cell Biol. 1993;13:6012–23.PubMedCentralPubMed
50.
Shimobayashi M, Hall MN. Making new contacts: the mTOR network in metabolism and signalling crosstalk. Nat Rev Mol Cell Biol. 2014;15:155–62. doi:10.1038/nrm3757.PubMed
51.
Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell. 2006;124:471–84.PubMed
52.
Jacinto E, Facchinetti V, Liu D, Soto N, Wei S, Jung SY, et al. SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell. 2006;127:125–37.PubMed
53.
Pearce LR, Huang X, Boudeau J, Pawłowski R, Wullschleger S, Deak M, et al. Identification of Protor as a novel Rictor-binding component of mTOR complex-2. Biochem J. 2007;405:513–22.PubMedCentralPubMed
54.
Martin J, Masri J, Bernath A, Nishimura RN, Gera J. Hsp70 associates with Rictor and is required for mTORC2 formation and activity. Biochem Biophys Res Commun. 2008;372:578–83. doi:10.1016/j.bbrc.2008.05.086.PubMedCentralPubMed
55.
Fingar DC, Blenis J. Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene. 2004;23:3151–71.PubMed
56.
Dibble CC, Manning BD. Signal integration by mTORC1 coordinates nutrient input with biosynthetic output. Nat Cell Biol. 2013;15:555–64. doi:10.1038/ncb2763.PubMedCentralPubMed
57.
Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012;149:274–93. doi:10.1016/j.cell.2012.03.017.PubMedCentralPubMed
58.
Morita M, Gravel SP, Hulea L, Larsson O, Pollak M, St-Pierre J, et al. mTOR coordinates protein synthesis, mitochondrial activity and proliferation. Cell Cycle. 2015;14:473–80. doi:10.4161/15384101.2014.991572.PubMed
59.
Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, Bagley AF, et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell. 2006;22:159–68.PubMed
60.
Oh WJ, Jacinto E. mTOR complex 2 signaling and functions. Cell Cycle. 2011;10:2305–16.PubMedCentralPubMed
61.
Anelli T, Sitia R. Protein quality control in the early secretory pathway. EMBO J. 2008;27:315–27. doi:10.1038/sj.emboj.7601974.PubMedCentralPubMed
62.
Hegde RS, Ploegh HL. Quality and quantity control at the endoplasmic reticulum. Curr Opin Cell Biol. 2010;22:437–46. doi:10.1016/j.ceb.2010.05.005.PubMedCentralPubMed
63.
Stone KR, Smith RE, Joklik WK. Changes in membrane polypeptides that occur when chick embryo fibroblasts and NRK cells are transformed with avian sarcoma viruses. Virology. 1974;58:86–100.PubMed
64.
Shiu RP, Pouyssegur J, Pastan I. Glucose depletion accounts for the induction of two transformation-sensitive membrane proteins in Rous sarcoma virus-transformed chick embryo fibroblasts. Proc Natl Acad Sci U S A. 1977;74:3840–4.PubMedCentralPubMed
65.
Ma Y, Hendershot LM. The unfolding tale of the unfolded protein response. Cell. 2001;107:827–30.PubMed
66.
Dudek J, Benedix J, Cappel S, Greiner M, Jalal C, Müller L, et al. Functions and pathologies of BiP and its interaction partners. Cell Mol Life Sci. 2009;66:1556–69.PubMed
67.
Cybulsky AV. The intersecting roles of endoplasmic reticulum stress, ubiquitin- proteasome system, and autophagy in the pathogenesis of proteinuric kidney disease. Kidney Int. 2013;84:25–33.PubMed
68.
Cunard R, Sharma K. The endoplasmic reticulum stress response and diabetic kidney disease. Am J Physiol Renal Physiol. 2011;300:F1054–61.PubMedCentralPubMed
69.
Cybulsky AV, Takano T, Papillon J, Khadir A, Liu J, Peng H. Complement C5b-9 membrane attack complex increases expression of endoplasmic reticulum stress proteins in glomerular epithelial cells. J Biol Chem. 2002;277:41342–51.PubMed
70.
Cybulsky AV, Takano T, Papillon J, Bijian K. Role of the endoplasmic reticulum unfolded protein response in glomerular epithelial cell injury. J Biol Chem. 2005;280:24396–403.PubMed
71.
Inagi R, Nangaku M, Usuda N, Shimizu A, Onogi H, Izuhara Y, et al. Novel serpinopathy in rat kidney and pancreas induced by overexpression of megsin. J Am Soc Nephrol. 2005;16:1339–49.PubMed
72.
Inagi R, Nangaku M, Onogi H, Ueyama H, Kitao Y, Nakazato K, et al. Involvement of endoplasmic reticulum (ER) stress in podocyte injury induced by excessive protein accumulation. Kidney Int. 2005;68:2639–50.PubMed
73.
Chen YM, Zhou Y, Go G, Marmerstein JT, Kikkawa Y, Miner JH. Laminin β2 gene missense mutation produces endoplasmic reticulum stress in podocytes. J Am Soc Nephrol. 2013;24:1223–33. doi:10.1681/ASN.2012121149.PubMedCentralPubMed
74.
Pippin JW, Brinkkoetter PT, Cormack-Aboud FC, Durvasula RV, Hauser PV, Kowalewska J, et al. Inducible rodent models of acquired podocyte diseases. Am J Physiol Renal Physiol. 2009;296:F213–29. doi:10.1152/ajprenal.90421.2008.PubMed
75.
Yan K, Khoshnoodi J, Ruotsalainen V, Tryggvason K. N-linked glycosylation is critical for the plasma membrane localization of nephrin. J Am Soc Nephrol. 2002;13:1385–9.PubMed
76.
Fujii Y, Khoshnoodi J, Takenaka H, Hosoyamada M, Nakajo A, Bessho F, et al. The effect of dexamethasone on defective nephrin transport caused by ER stress: a potential mechanism for the therapeutic action of glucocorticoids in the acquired glomerular diseases. Kidney Int. 2006;69:1350–9.PubMed
77.
Ozcan U, Ozcan L, Yilmaz E, Düvel K, Sahin M, Manning BD, et al. Loss of the tuberous sclerosis complex tumor suppressors triggers the unfolded protein response to regulate insulin signaling and apoptosis. Mol Cell. 2008;29:541–51. doi:10.1016/j.molcel.2007.12.023.PubMedCentralPubMed
78.
Kato H, Nakajima S, Saito Y, Takahashi S, Katoh R, Kitamura M. mTORC1 serves ER stress-triggered apoptosis via selective activation of the IRE1-JNK pathway. Cell Death Differ. 2012;19:310–20. doi:10.1038/cdd.2011.98.PubMedCentralPubMed
79.
Ito N, Nishibori Y, Ito Y, Takagi H, Akimoto Y, Kudo A, et al. mTORC1 activation triggers the unfolded protein response in podocytes and leads to nephrotic syndrome. Lab Invest. 2011;91:1584–95. doi:10.1038/labinvest.2011.135.PubMed
80.
Li Y, Xu S, Giles A, Nakamura K, Lee JW, Hou X, et al. Hepatic overexpression of SIRT1 in mice attenuates endoplasmic reticulum stress and insulin resistance in the liver. FASEB J. 2011;25:1664–79. doi:10.1096/fj.10-173492.PubMedCentralPubMed
81.
Inoki K, Mori H, Wang J, Suzuki T, Hong S, Yoshida S, et al. mTORC1 activation in podocytes is a critical step in the development of diabetic nephropathy in mice. J Clin Invest. 2011;121:2181–96. doi:10.1172/JCI44771.PubMedCentralPubMed
82.
Daniel C, Ziswiler R, Frey B, Pfister M, Marti HP. Proinflammatory effects in experimental mesangial proliferative glomerulonephritis of the immunosuppressive agent SDZ RAD, a rapamycin derivative. Exp Nephrol. 2000;8:52–62.PubMed
83.
Ramaiah A, Hathaway JA, Atkinson DE. Adenylate as a metabolic regulator. Effect on yeast phosphofructokinase kinetics. J Biol Chem. 1964;239:3619–22.PubMed
84.
Hardie DG, Hawley SA. AMP-activated protein kinase: the energy charge hypothesis revisited. Bioessays. 2001;23:1112–9.PubMed
85.
Reiser J, von Gersdorff G, Loos M, Oh J, Asanuma K, Giardino L, et al. Induction of B7-1 in podocytes is associated with nephrotic syndrome. J Clin Invest. 2004;113:1390–7.PubMedCentralPubMed
86.
Beutler B, Rietschel ET. Innate immune sensing and its roots: the story of endotoxin. Nat Rev Immunol. 2003;3:169–76.PubMed
87.
Carpenter S, O’Neill LA. Recent insights into the structure of toll-like receptors and post-translational modifications of their associated signalling proteins. Biochem J. 2009;422:1–10. doi:10.1042/BJ20090616.PubMed
88.
Asanuma K, Kim K, Oh J, Giardino L, Chabanis S, Faul C, et al. Synaptopodin regulates the actin-bundling activity of alpha-actinin in an isoform-specific manner. J Clin Invest. 2005;115:1188–98.PubMedCentralPubMed
89.
Oberbauer R, Segoloni G, Campistol JM, Kreis H, Mota A, Lawen J, et al. Rapamune maintenance regimen study group: early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation. Transpl Int. 2005;18:22–8.PubMed
90.
Schena FP, Pascoe MD, Alberu J, del Carmen RM, Oberbauer R, Brennan DC, et al. Sirolimus CONVERT trial study group: conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation. 2009;87:233–42. doi:10.1097/TP.0b013e3181927a41.PubMed
91.
Alberu J, Pascoe MD, Campistol JM, Schena FP, Rial Mdel C, Polinsky M, et al. Sirolimus CONVERT trial study group: lower malignancy rates in renal allograft recipients converted to sirolimus-based, calcineurin inhibitor-free immunotherapy: 24-month results from the CONVERT trial. Transplantation. 2011;92:303–10. doi:10.1097/TP.0b013e3181927a41.PubMed
92.
Serra AL, Poster D, Kistler AD, Krauer F, Raina S, Young J, et al. Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N Engl J Med. 2010;363:820–9. doi:10.1056/NEJMoa0907419.PubMed
93.
Kaplan B, Qazi Y, Wellen JR. Strategies for the management of adverse events associated with mTOR inhibitors. Transplant Rev (Orlando). 2014;28:126–33. doi:10.1016/j.trre.2014.03.002.
94.
Pape L, Ahlenstiel T, Ehrich JH, Offner G. Reversal of loss of glomerular filtration rate in children with transplant nephropathy after switch to everolimus and low-dose cyclosporine A. Pediatr Transplant. 2007;11:291–5.PubMed
95.
Ettenger R, Hoyer PF, Grimm P, Webb N, Loirat C, Mahan JD, et al. Everolimus pediatric study group. Multicenter trial of everolimus in pediatric renal transplant recipients: results at three year. Pediatr Transplant. 2008;12:456–63. doi:10.1111/j.1399-3046.2007.00832.x.PubMed
96.
Bumbea V, Kamar N, Ribes D, Esposito L, Modesto A, Guitard J, et al. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus. Nephrol Dial Transplant. 2005;20:2517–23.PubMed
97.
Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med. 2002;8:128–35.PubMed
98.
Ko HT, Yin JL, Wyburn K, Wu H, Eris JM, Hambly BD, et al. Sirolimus reduces vasculopathy but exacerbates proteinuria in association with inhibition of VEGF and VEGFR in a rat kidney model of chronic allograft dysfunction. Nephrol Dial Transplant. 2013;28:327–36. doi:10.1093/ndt/gfs453.PubMed
99.
Schrijvers BF, Flyvbjerg A, De Vriese AS. The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. Kidney Int. 2004;65:2003–17.PubMed
100.
Eremina V, Sood M, Haigh J, Nagy A, Lajoie G, Ferrara N, et al. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest. 2003;111:707–16.PubMedCentralPubMed
101.
Olszewska A, Szewczyk A. Mitochondria as a pharmacological target: magnum overview. IUBMB Life. 2013;65:273–81. doi:10.1002/iub.1147.PubMed
102.
Bayeva M, Gheorghiade M, Ardehali H. Mitochondria as a therapeutic target in heart failure. J Am Coll Cardiol. 2013;61:599–610. doi:10.1016/j.jacc.2012.08.1021.PubMedCentralPubMed
103.
Zhan M, Brooks C, Liu F, Sun L, Dong Z. Mitochondrial dynamics: regulatory mechanisms and emerging role in renal pathophysiology. Kidney Int. 2013;83:568–81. doi:10.1038/ki.2012.441.PubMedCentralPubMed
104.
Nicolaides NC, Galata Z, Kino T, Chrousos GP, Charmandari E. The human glucocorticoid receptor: molecular basis of biologic function. Steroids. 2010;75:1–12. doi:10.1016/j.steroids.2009.09.002.PubMedCentralPubMed
105.
Heitzer MD, Wolf IM, Sanchez ER, Witchel SF, DeFranco DB. Glucocorticoid receptor physiology. Rev Endocr Metab Disord. 2007;8:321–30.PubMed
106.
Yan K, Kudo A, Hirano H, Watanabe T, Tasaka T, Kataoka S, et al. Subcellular localization of glucocorticoid receptor protein in the human kidney glomerulus. Kidney Int. 1999;56:65–73.PubMed
107.
Kataoka S, Kudo A, Hirano H, Kawakami H, Kawano T, Higashihara E, et al. 11beta-hydroxysteroid dehydrogenase type 2 is expressed in the human kidney glomerulus. J Clin Endocrinol Metab. 2002;87:877–82.PubMed
Related posts:
History of Research on Pathogenesis of Idiopathic Nephrotic Syndrome
Regulatory T Cells and Oxidative Stress in Minimal Change Nephropathy
Cytokines as Active Factors in Focal Segmental Glomerulosclerosis
Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) in Focal Segmental Glomerulosclerosis
Podocytes as a Direct Target of Drugs Used in Idiopathic Nephrotic Syndrome
Angiopoietin-Like 4 (Angptl4) in MCNS
